Brain-computer interfaces

Core thesis

Invasive BCI has moved from first-in-human (Neuralink, 2024) to small but growing cohorts – roughly 26 Neuralink participants by mid-2026 – with Synchron offering a less invasive endovascular route via blood vessels and heading into the first FDA pivotal trial. The near-term value is therapeutic: restoring communication and movement for paralysed and severe-speech-loss patients, a niche of perhaps tens of thousands. The long-term vision (cognitive enhancement, memory augmentation) remains years to decades away. Three things still stand between the technology and a real market: whether electrodes hold a stable signal for years, whether payers will reimburse, and whether the surgical risk is justified for each indication.

State of the art (2026)

Brain implants that let paralysed people control devices are still in clinical trials. Neuralink and Synchron are both testing implants in patients, and Synchron's catheter-delivered device remains investigational with no commercial approval. Precision Neuroscience's Layer 7-T cortical electrode received FDA 510(k) clearance on 30 March 2025. That clearance covers an electrode placed on the surface of the brain, and it is a lower bar than the premarket approval a permanent implant would need. The open questions are how long electrodes keep working in the brain, who will pay, and whether devices worn outside the skull can catch up.